Background: Atopy is defined as excess allergen-specific IgE (A-IgE). IgE is produced by plasma cells that differentiate from allergen-specific B cells. B cells are known to be killed by chemotherapy; however, it is not known whether A-IgE-secreting plasma cells are killed or inhibited by chemotherapy. If yes, serum A-IgE levels would be expected to decrease after chemotherapy. Objectives: We aimed to determine whether A-IgE levels in atopic individuals (serum A-IgE ≥0.35 kUA/L) decrease into the nonatopic range (< 0.35 kUA/L) after chemotherapy. Methods: In 105 patients undergoing chemotherapy for acute leukemia, we measured serum A-IgE before and after chemotherapy. In a subset of these patients, we also measured B cell counts before and after chemotherapy. Results: Of the 105 patients, 36 were atopic. In these patients, median A-IgE level before chemotherapy was 1.6 kUA/L whereas the median level after chemotherapy was 0.6 kUA/L (p < 0.001). In 12/36 (33%) patients, A-IgE levels decreased into the nonatopic range. In nonatopic patients (n = 69), the median A-IgE level also dropped: from 0.04 kUA/L before to 0.03 kUA/L after chemotherapy (p = 0.001). Among the total patients (n = 105), the median pre:post-chemotherapy A-IgE ratio was 1.8 (2.6 in atopic and 1.5 in nonatopic patients). In contrast, the median ratio of pre:post-chemotherapy B cell counts was 87.6. Conclusions: A-IgE levels decrease after chemotherapy but markedly less than B cell counts. Thus, at least some A-IgE plasma cells appear to survive chemotherapy.

Keywords:
Atopy, B lymphocytes, Chemotherapy, IgE, Plasma cells
1.
Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA, Carter CR: Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res 2016; 18: 10.
2.
Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL, Gress RE: Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84: 2221–2228.
3.
Kantar M, Cetingul N, Kansoy S, Kutukculer N, Aksu G: Immune deficiencies following cancer treatment in children. J Trop Pediatr 2003; 49: 286–290.
4.
Kurtenkov O, Klaamas K, Rittenhouse-Olson K, Vahter L, Sergejev B, Miljukhina L, Shljapnikova L: IgG immune response to tumor- associated carbohydrate antigens (TF, Tn, αGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival. Exp Oncol 2005; 27: 136–140.
5.
Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, Hanifin JM, Slifka MK: Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9: 1131–1137.
6.
Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, Stevens J, Wilson IA, Aguilar PV, Altshuler EL, Basler CF, Crowe JE Jr: Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455: 532–536.
7.
Holt PG, Sedgwick JD, O’Leary C, Krska K, Leivers S: Long-lived IgE- and IgG-secreting cells in rodents manifesting persistent antibody responses. Cell Immunol 1984; 89: 281–289.
8.
Ndungu FM, Cadman ET, Coulcher J, Nduati E, Couper E, Macdonald DW, Ng D, Langhorne J: Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice. PLoS Pathog 2009; 5:e1000690.
9.
Luger EO, Fokuhl V, Wegmann M, Abram M, Tillack K, Achatz G, Manz RA, Worm M, Radbruch A, Renz H: Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge. J Allergy Clin Immunol 2009; 124: 819–826.
10.
Mitre E, Nutman TB: IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections. J Allergy Clin Immunol 2006; 117: 939–945.
11.
Cooling LL, Sherbeck J, Mowers JC, Hugan SL: Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation. Immunohematology 2017; 33: 15–21.
12.
Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte- associated antigen 4. J Clin Oncol 2006; 24: 2283–2289.
13.
Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, Sprod LK, Heckler CE, Roscoe JA, Katz AW, Williams JP, Morrow GR: Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer 2012; 20: 831–839.
14.
Heyd J, Donnenberg AD, Burns WH, Saral R, Santos GW: Immunoglobulin E levels following allogeneic, autologous, and syngeneic bone marrow transplantation: an indirect association between hyperproduction and acute graft-v-host disease in allogeneic BMT. Blood 1988; 72: 442–446.
15.
Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S: Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008; 50: 822–825.
16.
Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F: Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003; 101: 3857–3861.
17.
Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med 2005; 353; 1711–1723.
18.
Settipane GA, Pudupakkam RK, McGowan JH: Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol 1978; 62: 162–166.
19.
Abdel Razik A, Shaheen A, Shaheen F: The effect of beclomethasone inhalation and oral montelukast sodium on serum IgE levels and clinical parameters in asthmatic children. Alexandria J Pediatr 2005; 19: 341–346.
20.
Ohrui T, Funayama T, Sekizawa K, Yamaya M, Sasaki H: Effects of inhaled beclomethasone dipropionate on serum IgE levels and clinical symptoms in atopic asthma. Clin Exp Allergy 1999; 29: 357–361.
21.
Ho F, Lortan JE, MacLennan IC, Khan M: Distinct short-lived and long-lived antibody-producing cell populations. Eur J Immunol 1986; 16: 1297–1301.
22.
Dreskin SL, Goldsmith PK, Strober W: Metabolism of immunoglobulin E in patients with markedly elevated serum immunoglobulin E levels. J Clin Invest 1987; 79: 1764–1772.
23.
Valent P, Blatt K, Eisenwort G, Herrmann H, Cerny-Reiterer S, Thalhammer R, Mullauer L, Hoermann G, Sadovnik I, Schwarzinger I, Sperr WR, Mannhalter C, Horny H-P: FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7; 10)(q22;q26) and KIT D816H. Leuk Res Rep 2014; 3: 8–13.
24.
Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutre SE: Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865–2870.
25.
Jones PD, Henry RL, Francis L, Gibson PG: Chemotherapy reduces the prevalence of asthma symptoms in children with cancer: implications for the role of airway inflammation in asthma. J Paediatr Child Health 1999; 35: 269–271.
26.
Weigel S, Schmidt SM, Bernig T, Mukodzi S, Beck JF, Ballke EH, Wiersbitzsky SK: Intensive chemotherapeutic regimens against acute leukemia transiently suppress asthma symptoms but do not lead to long-term relief. Pediatr Hematol Oncol 2000; 17: 659–665.
27.
Geha RS, Rappaport JM, Twarog FJ, Parkman R, Rosen FS: Increased serum immunoglobulin E levels following allogeneic bone marrow transplantation. J Allergy Clin Immunol 1980; 66: 78–81.
28.
Bengtsson M, Gordon J, Flores-Romo L, Cairns JA, Smedmyr B, Oberg G, Simonsson B, Totterman TH: B-cell reconstitution after autologous bone marrow transplantation: increase in serum CD23 (“IgE-binding factor”) precedes IgE and B-cell regeneration. Blood 1981; 73: 2139–2144.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.